Blog
RSS FeedPosted by Michael Wonder on 29 Sep 2023
Pfizer and BioNTech receive Health Canada authorisation for XBB.1.5 adapted monovalent COVID-19 vaccine
28 September 2023 - The updated vaccine is expected to be available in Canada in the coming weeks. ...
Posted by Michael Wonder on 13 Sep 2023
Health Canada authorises Moderna COVID-19 vaccine targeting the Omicron XBB.1.5 sub-variant
12 September 2023 - Health Canada has authorised the use of the Moderna Spikevax COVID-19 vaccine targeting the Omicron XBB.1.5 ...
Posted by Michael Wonder on 29 Aug 2023
Health Canada accepts Valneva’s Chikungunya vaccine license application for review
29 August 2023 - Valneva today announced that Health Canada has completed screening validation of the Company’s regulatory application for ...
Posted by Michael Wonder on 05 Aug 2023
GSK's Arexvy, the first respiratory syncytial virus vaccine for older adults approved in Canada
4 August 2023 - Approval of Arexvy was based on a comprehensive Phase III clinical trial program that showed high vaccine ...
Posted by Michael Wonder on 30 Jun 2023
Moderna initiates rolling submission to Health Canada for updated COVID-19 vaccine
29 June 2023 - Health Canada submission follows international recommendations to develop monovalent XBB.1.5 COVID-19 vaccines. ...
Posted by Michael Wonder on 30 May 2023
Valneva files for Chikungunya vaccine authorisation with Health Canada
30 May 2023 - Valneva today announces the filing of a regulatory application with Health Canada for marketing approval of ...
Posted by Michael Wonder on 15 Apr 2023
Pfizer Canada initiates submission to Health Canada for its bivalent respiratory syncytial virus vaccine
14 April 2023 - Indications under review include prevention of respiratory syncytial virus in infants from birth through 6 months ...
Posted by Michael Wonder on 19 Feb 2023
Health Canada authorises Moderna's Omicron targeting bivalent COVID-19 vaccine in children & adolescents (6-17 years)
17 February 2023 - The recommendation is based on clinical data for Moderna's bivalent Omicron targeting COVID-19 vaccine, mRNA.1273.214. ...
Posted by Michael Wonder on 10 Dec 2022
Health Canada authorises the Pfizer-BioNTech Omicron BA.4/BA.5 bivalent adapted COVID-19 booster for children 5 to 11 years of age
9 December 2022 - Today, Health Canada authorised the Pfizer-BioNTech Comirnaty Omicron BA.4/BA.5 bivalent adapted booster for use in children 5 ...
Posted by Michael Wonder on 10 Dec 2022
VBI Vaccines announces Health Canada approval for PreHevbrio for the prevention of hepatitis B in adults
8 December 2022 - VBI Vaccines today announced that Health Canada has approved PreHevbrio [3 antigen hepatitis B vaccine (recombinant)] for ...
Posted by Michael Wonder on 07 Dec 2022
Novavax Nuvaxovid COVID-19 vaccine approved in Canada for use as a primary series in adolescents
7 December 2022 - Novavax today announced that Health Canada has approved a supplement to a new drug submission for Nuvaxovid ...
Posted by Michael Wonder on 26 Nov 2022
GSK Canada submits respiratory syncytial virus vaccine candidate for regulatory review
25 November 2022 - Application includes important pivotal Phase 3 data evaluating the efficacy and safety of our vaccine candidate against ...
Posted by Michael Wonder on 19 Nov 2022
Novavax’s COVID-19 booster has been approved for adults, Health Canada says
17 November 2022 - Health Canada said Thursday it has approved the booster dose of Novavax‘s Nuvaxovid COVID-19 vaccine for ...
Posted by Michael Wonder on 06 Nov 2022
Moderna receives Health Canada authorisation for second Omicron targeting bivalent booster
4 November 2022 - mRNA-1273.222 targets BA.4/BA.5 Omicron sub-variants and follows the approval of mRNA-1273.214 (SPIKEVAX Bivalent) in Canada, which ...
Posted by Michael Wonder on 03 Nov 2022
Health Canada authorises second bivalent COVID-19 booster targeting the Omicron BA.4/5 variants
3 November 2022 - Today, Health Canada authorised an adapted version of the Moderna Spikevax COVID-19 vaccine that targets the Omicron ...